Tag: review

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI

Laguna Hills, CA, June 15, 2026 (GLOBE NEWSWIRE) -- Glitter Bug Gold Buyers announced that the company has achieved accreditation from the Better Business Bureau (BBB) and currently maintains an A+ rating. The accreditation recognizes the company's commitment to ethical business practices, transparency, customer service standards, and marketplace integrity as it continues serving precious metals sellers throughout Orange County.

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- PAVS (NASDAQ:PAVS) (the "Company"), a consumer products and digital commerce solutions company, today announced that it has entered into a definitive agreement with certain institutional investors for a registered direct offering of an aggregate of 50,000,000 Class A ordinary shares (or pre-funded warrants to purchase Class A ordinary shares in lieu thereof) at a purchase price of $0.20 per share. The gross proceeds to the Company from the offering are expected to be approximately $10 million, before deducting offering expenses.

La Hulpe, Belgium - 15 June 2026, 7:00 a.m. CET – INSIDE INFORMATION - Banqup Group SA (Euronext Brussels: BANQ) (“Banqup” or the “Company”) today announces that, following an extensive review, the Board has approved a strategic simplification plan to reorganize the Group into distinct, autonomous business units to enhance operational focus and transparency. Lazard is mandated to explore all strategic options, including the sale of individual business units or the Group as a whole in order to maximize stakeholder value.

ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31^st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.